Meta-analysis studies suggest that EGFR-TKIs improves progression-free survival (PFS) in patients with advanced NSCLC expressing mutant EGFR whilst having no significant impact in NSCLC patients with NSCLC expressing wild-type EGFR [65–69]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.